Equity Research Analysis: HELIUS MEDICAL TECHNOLOGIES, INC. (HSDT)
|Blank Capital Research Unit|Spot: $1.87
Price$1.87
Composite Score32.8/100
RatingAVOID (1★)
Rank#4309 OF 7,333
Market Cap$16M
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4309
Positioning
Market Dominance
Manufacturing
Medical Equipment
$16M
Dane C. Andreeff
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company is headquartered in Newtown, Pennsylvania.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HSDT HELIUS MEDICAL TECHNOLOGIES, INC. | 33 | 36 | 21 | 50 | - | - | 498.5% | -77.8% | -112.9% | -7244.4% | -22135.0% | 283.0% | 0.0% | - | $16M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
HELIUS MEDICAL TECHNOLOGIES, INC. (HSDT) receives a "Avoid" rating with a composite score of 32.8/100. It ranks #4309 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for HSDT.
View All RatingsROE proxy 498.5% (sector -1.9%)
GM -113% vs sector 44%, OM -7244% vs sector 3%
Capital turnover N/A, R&D intensity 332.7%
Rev growth 283%, 10yr history
Interest coverage -0.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate HELIUS MEDICAL TECHNOLOGIES, INC. (HSDT) as Avoid with a composite score of 32.8/100 at a current price of $1.87. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
HELIUS MEDICAL TECHNOLOGIES, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 32.8/100 places it at rank #4309 in our full universe.
No Moat
Very High
Poor
Fair Value
Returns on equity of 498.5% exceed cost of capital.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
HELIUS MEDICAL TECHNOLOGIES, INC. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags HELIUS MEDICAL TECHNOLOGIES, INC. with an Avoid rating, assigning a composite score of 32.8/100 and 1 out of 5 stars. Ranked #4309 of 7,333 stocks, HSDT falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
HSDT's quality score of 36/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 498.5% (sector avg: -1.9%), gross margins of -112.9% (sector avg: 44.1%), net margins of -22135.0% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
HSDT registers a value score of just 21/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
HELIUS MEDICAL TECHNOLOGIES, INC.'s investment score of 21/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 283.0% vs. a sector average of 6.7% and a return on assets of -77.8% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
HSDT demonstrates moderate momentum with a score of 50/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 283.0% year-over-year, while a beta of 6.54 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
HELIUS MEDICAL TECHNOLOGIES, INC. registers a low stability score of 4/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 6.54. Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
HELIUS MEDICAL TECHNOLOGIES, INC.'s short interest score of 31/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 6.54), micro-cap liquidity risk. At $16M (micro-cap), HSDT carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
HELIUS MEDICAL TECHNOLOGIES, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4309 of 7,333 overall (41st percentile). Key comparisons include ROE of 498.5% exceeding the -1.9% sector median and operating margins of -7244.4% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HSDT currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (4) would have the largest impact on the composite score.
ROE 26337% BELOW SECTOR MEDIAN
Gross Margin 356% BELOW SECTOR MEDIAN
Op. Margin 288723% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
The move comes despite a series of recent pullbacks in the crypto market that saw bitcoin trade at around $85,000 earlier this month.
Deployment to be focused on Asia-Pacific region to capitalize on fast-growing wealth accumulation, cross-border payments, and institutional adoption of digital assetsExpansion planned to enable Solana Company to capture more value
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
This article explores Hyperion DeFi, Inc. (NASDAQ: HYPD), which represents a unique bridge between traditional finance and decentralized finance (DeFi). The company's digital asset treasury core holdings are Hyperliquid's HYPE token and KNTQ token.